The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a greater substantial loss in body mass and benefit metabolic func